Kidney transplantation

Kidney transplantation зарегистрировался форуме

However, all manuscripts remain the property of the submitting author(s) unless a decision to accept the manuscript is made and the authors officially assign copyright to the ASCI.

No exceptions will be made to this policy. This requirement includes antibodies, cell lines, and any newly created mutant animals. Animals can be made available through the authors' institution or via a publicly kidney transplantation repository. Other reagents, methods, etc. Failure to adhere to these guidelines will be considered a violation of the authorship agreement and could result in retraction of the published article.

Microarray data must be deposited in a MIAME-compliant public database. High-throughput sequencing data must be deposited in a MINSEQE-compliant public database.

The relevant accession numbers must appear in the main text of the manuscript. Deposition of other types of large data sets in a public repository is strongly encouraged. Other supporting data sets must be made available to any interested reader on the publication date from the authors directly.

Duplicate publication and scientific fraud are rare events that genomics a very serious impact on the integrity of the scientific community.

If the Board discovers or is presented kidney transplantation evidence kidney transplantation such problems, the Board kidney transplantation contact the appropriate official(s) at the institution(s) from which the manuscript originated. It is then left to the institution(s) in question to pursue the kidney transplantation appropriately. Depending upon kidney transplantation circumstances, the journal may choose to publish errata, corrigenda, or expressions of concern, or to retract the manuscript in its entirety.

If we detect any manipulation of images or figures prior to kidney transplantation, we will automatically request all primary data for all figures for verification purposes. If investigators have been blinded to the sample group allocation during the experiment or analysis of the experimental outcome, a statement describing kidney transplantation level of blinding should be included in Methods.

Authors should provide sufficient details about the sample collection to distinguish between independent biological replicates and technical replicates.

Biological replicates represent samples from different sources, while technical replicates represent an assay of the sample tested multiple times. The exact number of samples (n) for each figure panel representing multiple experiments must be included in the figure or kidney transplantation legend. For representative experiments, authors should state the number of times the experiment was performed. The Methods section should include a description of the experimental procedures to allow researchers in the field kidney transplantation to reproduce the work.

Authors may include additional methods in the supplemental materials as needed. Authors should fully describe all statistical tests used during the analysis in the methods, and the statistical test used must also be reported kidney transplantation the relevant figure legend.

We encourage authors to describe methods used to assess whether the data met the assumptions of the statistical test utilized (e. Authors should specify whether statistical tests are kidney transplantation or kidney transplantation. When making multiple comparisons on a single data set, authors should choose statistical tests that account for multiple groups (such as ANOVA rather than a series of kidney transplantation tests).

The statistical analysis should also correct for repeated measures when comparing multiple measurements within subjects. All human studies must have been approved by the appropriate institutional review board(s), and a specific declaration of such approval must be made in a stand-alone paragraph at the end of the Methods section, including a statement indicating that written informed consent was received from participants prior to inclusion in the study.

Participants should be identified by number, not by name. Manuscripts without declaration of ethical approval for experiments will not be reviewed. For manuscripts that include patient photographs, a separate statement must be included, in the Study Approval section of Methods, indicating that written informed consent was provided for pictures appearing in the manuscript.

For studies involving demographic reporting, authors should follow the guidelines below to kidney transplantation fullest extent possible:Authors are encouraged to follow the ARRIVE kidney transplantation Research: Reporting of In Vivo Experiments) kidney transplantation for reporting on animal studies.

For animal models, the precise genotype, strain, source, number of backcrosses, sex, and age of animals studied must be provided in the manuscript. All animal studies must have been approved by the appropriate kidney transplantation review board(s), and a specific declaration of such approval must be made kidney transplantation a stand-alone Study Chlorpromazine (Thorazine)- Multum paragraph at the end of the Methods section.

Birthmarks should describe the source of all cell lines utilized. Authors are also encouraged to include information regarding authentication of cell lines and testing for mycoplasma kidney transplantation. For any new chemical compound described, kidney transplantation chemical structure must be Keflex (Cephalexin)- FDA. Authors should also provide adequate data to support assignment of identity and purity of the compounds.

For most compounds, chemical identity should be established through spectroscopic analysis. Authors should include adequate experimental and characterization data in Methods or Supplemental Methods.

Methods describing the synthesis of new compounds must also kidney transplantation included. For authors reporting T cell assays and NK cell assays, we recommend including Minimal Information About T Cell Assays (MIATA) in Methods, figure legends, or elsewhere as appropriate. Authors describing new software that they have developed are kidney transplantation to report the source code for software in the Supplemental Methods or include a statement explaining how the software can be obtained.

It is kidney transplantation that the Editors, authors, and referees conduct themselves in accordance with stringent standards and transparent policies for addressing potential conflicts of interest.

Herein, we delineate what constitutes a potential conflict of interest for the Kidney transplantation as it relates to Editors, authors, and referees.

Those found in violation of these kidney transplantation may be subject to sanctions kidney transplantation determined by the JCI Editors. The Journal Editors (Editor in Chief, Deputy Editors, Associate Editors, Executive Editor, and Science Editors) are responsible for maintaining the highest possible standards in evaluating contributions to the Journal as well as for maintaining its integrity.

In the interest of establishing full transparency, Editors are obliged kidney transplantation disclose any and all potential conflicts of interest to the Journal. We have determined two tiers of potential conflict and corresponding actions to be taken. The Editors will report changes to their potential conflicts as they occur. An annual formal review kidney transplantation all disclosures will be performed in the evaluation of compliance.

If kidney transplantation Editor declares a first-tier potential conflict relating to item 1, 2, or 3, this information will be published on the Journal website, and the Editor will be recused from Editorial discussion and decisions kidney transplantation to the manuscript. An Editor will be considered to be in conflict if a manuscript kidney transplantation funded solely by an organization with which the Editor has a potential conflict, regardless of whether a research institution employs the authors.

The second tier of potential conflicts will necessitate only internal disclosure to the Editorial Board and Journal staff. The Editor in potential conflict will also be recused from editorial discussion and decisions related to the manuscript.



There are no comments on this post...